Naturally Acquired and Conjugate Vaccine-Induced Antibody to *Haemophilus influenzae* Type b (Hib) Polysaccharide in Malian Children: Serological Assessment of the Hib Immunization Program in Mali

Julia Hutter,* Marcela F. Pasetti, Doh Sanogo, Milagritos D. Tapia, Samba O. Sow, and Myron M. Levine

Center for Vaccine Development and the Departments of Pediatrics and Medicine, University of Maryland School of Medicine, Baltimore, Maryland; Centre pour le Développement des Vaccins, Mali, Bamako, Mali

Abstract. *Haemophilus influenzae* type b (Hib) conjugate vaccine for infants (6, 10, and 14 weeks of age) was introduced into the Malian Expanded Program on Immunization in July 2005, to diminish invasive Hib disease in young children. Antibodies to Hib capsular polysaccharide (PRP) were measured in infants and toddlers from an area already served by the Hib immunization program (Bamako) and in unimmunized children of the same age in a district (Kangaba) where Hib immunization had not yet begun. Among vaccinated Bamako children 6–23 months of age, 77–93% exhibited PRP titers ≥ 1.0 μg/mL, indicating long-term protection, versus only 10–23% of Kangaba children of that age. High PRP antibody titers in immunized children persisted through 2 years of age. Moreover, ~50% of Bamako children exhibited anti-PRP titers ≥ 5.0 μg/mL; a level that impedes Hib upper respiratory carriage, and may thereby diminish the Hib transmission to the unimmunized susceptible population (i.e., providing indirect protection).

INTRODUCTION

In the first years of the millennium, before the widespread introduction of conjugate vaccine to prevent invasive disease caused by *Haemophilus influenzae* type b (Hib) in developing countries, the World Health Organization (WHO) estimated that more than 3 million cases of invasive Hib disease, such as meningitis, pneumonia, and septicemia, and 380,000 deaths occurred annually in children younger than 5 years of age worldwide.1 Circa 2000, Africa had one of the highest regional burdens of Hib meningitis, with an incidence rate of ~60–70/100,000 in children younger than 5 years of age2,3 and a case-fatality rate of ~29%.2

The burden is highest in infants and toddlers, 4–18 months of age; Hib uncommonly affects children younger than 1 month or over 5 years of age.1 In the absence of immunization, the period of highest susceptibility commences as maternal antibodies begin to wane at ~4 months of age and before children naturally acquire bactericidal antibodies against Hib. Serum bactericidal antibodies are overwhelmingly mediated by serum immunoglobulin G (IgG) directed against polyribosylribitol phosphate (PRP), the Hib capsular polysaccharide. Typically, natural bactericidal antibodies acquired subsequent to upper respiratory colonization with Hib or with bacteria such as *Escherichia coli* K100 that express cross-reacting surface molecules do not appear until the second year of life.4,5

Hib polysaccharide-protein conjugate vaccines developed in the 1980s stimulate a T cell-dependent immune response, which leads to immunologic memory, and an immunoglobulin class switch with resultant increased antibody affinity and avidity.5–10

Accordingly, Hib conjugate vaccines are highly immunogenic, even in young infants.11–13 Introduction of Hib conjugate vaccines into the routine immunization schedule has led to near eradication of invasive Hib disease in many industrialized and transitional countries, and some developing countries.11,14–17

A serum anti-PRP titer ≥ 1.0 μg/mL, originally proposed by Kayhty and others18 is now widely accepted in vaccinology and public health as a titer that is associated with long-term protection against invasive Hib disease. Accordingly, this is the most frequently used measure to assess the immunogenicity of Hib conjugate immunization schedules and to predict protection that will endure throughout the period of risk for infants, toddlers, and pre-school children.10,19–23 Moreover, a study in the Dominican Republic has indicated that even higher serum PRP antibody levels, ≥ 5.0 μg/mL, can be correlated with protection against upper respiratory tract colonization with Hib.17

Since 2002, the Center for Vaccine Development - Mali (CVD-Mali), in Bamako (a collaborative enterprise maintained jointly by the Ministry of Health of Mali and the Center for Vaccine Development of the University of Maryland School of Medicine), has been conducting systematic surveillance studies of invasive pediatric bacterial infections among infants and children admitted to the government hospital where severely ill children are admitted.35 In the period June 2002 through May 2005, a high incidence of invasive Hib disease was documented—45.2/100,000 in children younger than 5 years of age, with a peak incidence rate of 370/100,000 in infants 6–7 months of age.35 A baseline serosurvey undertaken in Bamako before the introduction of Hib vaccine revealed that only 1.5% of 6–to-7-month-old infants had PRP antibody concentrations ≥ 0.15 μg/mL and only 0.5% had titers ≥ 1.0 μg/mL.35 Thus, in the absence of Hib immunization, Malian infants were serologically highly susceptible at the age of peak Hib disease incidence.

Hib conjugate was introduced into the Malian Expanded Program on Immunization (EPI) in a three-step program, beginning with Bamako in July 2005, followed by other urban areas in July 2006, and finally expanding to all infants country-wide in July 2007. In Mali, Hib vaccine (as a component of a pentavalent combination vaccine) is targeted to be administered to infants at 6 weeks, 10 weeks, and 14 weeks of age. In contrast with the immunization schedules used widely in North and South America and most European countries, Malian toddlers do not receive a reinforcing booster dose of Hib conjugate in the second year of life. Although serosurveys were performed to document the susceptibility of infants 6–7 months of age in Bamako,35 no data were available about the kinetics and persistence of the PRP antibody response following administration of pentavalent vaccine in Malian infants, nor were Hib
serosurvey data available from infants in rural areas. To fill these knowledge gaps, we conducted a cross-sectional survey of two populations, one Hib-vaccinated (urban Bamako) and the other Hib-unvaccinated (rural Kangaba). In each population, serum specimens were collected for testing from an age cross section of children representing subjects 6 weeks, 6 months, 12 months, 15 months, 18 months, and 23 months of age. The PRP titers in Bamako children were used to model the antibody response to the 3-dose Hib vaccination schedule and were compared with PRP titers in Kangaba children, which revealed the rate of acquisition of natural immunity to Hib (or lack thereof) in unvaccinated children.

MATERIALS AND METHODS

Study site. Mali is a land-locked country in Western Africa ranked among the six least developed countries, with an under 5 mortality rate of 191/1000 live births.36 Bamako, the capital city of 1.5 million inhabitants located on the Niger River in the southwestern part of the country, is the most populous city of Mali and is divided into six communes. Bamako’s population incorporates a diverse cultural and ethnic mix, including Bambara, Malinke, Dongo, Sarakole, Peuhl, and Sonrai. For the Hib-vaccinated study population (urban Bamako), a sample of children who live in Djikoroni-para and Banconi, two low socioeconomic level quarters within Commune 4 and Commune 1, respectively, were randomly selected from a demographic surveillance system database. Children for the Hib-unvaccinated study population represent a sample from rural Kangaba cercle, which lies in the Koulikoro region of Mali, ~100 km from the capital. The cercle has a population of 80,923 distributed over 60 villages. The population of Kangaba is mainly of Malinke ethnic background. At the time of our sample collection (2008) the national stepwise Hib vaccine implementation program had saturated Bamako but had not yet started in Kangaba. Because a demographic surveillance system is not maintained in rural Kangaba, CVD-Mali field staff used WHO immunization coverage survey methods to randomly select villages and to identify start points for the house-to-house searches for age-eligible children. At each household the staff inquired if there was an age-eligible child. If so, informed consent procedures were initiated to ascertain whether the parents or caretakers were willing to have their child participate. Twelve of the 60 villages were sampled, and the refusal rate was 3%.

Sample size calculations. On the basis of the data of Sow and others13,15 and Campagne and others,13 we assume that at least 75% of Hib-vaccinated children 6 months and older in Bamako would have a PRP antibody titer > 1 μg/mL,13,15 however no more than 20% of children in rural Kangaba who had not received Hib conjugate would likely have such titers.13,15 Thus, by comparing a sample of 30 subjects per specified age group from each site, we would have 84% power to detect a significant difference (α = 0.025, one-tail, Fisher’s exact test) if the prevalence of such titers of PRP antibody was no more than 35% for Hib-unvaccinated (Kangaba) versus 75% for Hib-vaccinated children (Bamako), respectively. Power calculations were done using PASS 2008 (Number Cruncher Statistical Systems, Kaysville, UT).

Study design. The study was conducted as a cross-sectional survey in which demographic data and immunization status were collected on each child and a serum specimen was collected and tested for PRP antibodies. Eligible participants were healthy children at 6 weeks and 6, 12, 15, 18, and 23 months of age in urban Bamako and rural Kangaba (each age group had a 2 week ± enrollment window). To be eligible, children in Bamako had to have evidence of immunization with three doses of pentavalent vaccine at 6 weeks of age (eligible range, age 6–12 weeks), 10 weeks (eligible range, age 10–18 weeks), and 14 weeks (eligible range, age 14–22 weeks); whereas children in Kangaba had to be vaccinated with diphtheria-tetanus-whole cell pertussis (DTwP) vaccine at 6 weeks of age (eligible range, age 6–12 weeks), 10 weeks (eligible range, age 10–18 weeks), and 14 weeks (eligible range, age 14–22 weeks), but not with Hib (i.e., pentavalent) vaccine. The interval between immunizations had to be at least 24 days.

The extended upper range for eligibility with respect to vaccination ages was necessary because in Mali immunization of infants often occurs several weeks beyond the recommended EPI target ages. The Hib vaccine administered, consisting of 10 μg of PRP covalently bound to 20–40 μg of tetanus toxoid (PRP-T), was a component of Tritanrix-HBV-TM pentavalent vaccine (GSK Biologicals, Rixensart, Belgium) that included DTwP and hepatitis B vaccines in a single syringe. The immunization history was confirmed by immunization card review; no oral reports or other medical records were accepted. Children were excluded from the study if they had received any blood products within the last 90 days; or if they had been vaccinated with Hib and were in the Kangaba study population.

Study review and informed consent. The study was approved by the Ethics Committee of the Malian Medical University (Faculté de Médecine, Pharmacologie et Odontostomatologie) and the Institutional Review Board of the University of Maryland, Baltimore, MD. The consent process involved obtaining initial concurrence from community leaders to work in the communities, followed by individual consent from parents or guardians with communication aids in local dialects and audio tapes for illiterate community members.

Specimen and data collection and laboratory methods. Initial interview, immunization card review, and sample collection all took place on the same day for participants who were included in the study. Blood was collected and processed at the respective local health facilities (CVD-Mali Clinical Unit in Djikoroni-para, the community health center in Banconi, or the community health center in Kangaba village), according to standard operating procedures. The blood samples were centrifuged to separate serum, which was then transported under cold chain to the CVD-Mali Immunology Laboratory. An aliquot of each serum specimen was shipped frozen to CVD-Baltimore and analyzed for anti-PRP antibodies using indirect enzyme-linked immunosorbent assay (ELISA). Briefly, Immunonol II plates (Thermo Labsystem, Franklin, MA) were coated with purified PRP (HbO-HA antigen, Lederle-Praxis Biologicals, Inc., Rochester, NY, Lot #17) at 1 μg/mL in phosphate buffered saline for 3 hours at 37°C and blocked with 10% dried milk (Nestle USA, Inc., Glendale, CA) overnight at 4°C. Sera were added in serial 2-fold dilutions along with the standard (CBER/FDA lot 1983; Center for Biologics and Evaluation Research, Food and Drug Administration, Bethesda, MD) and incubated for 1 hour at 37°C. Peroxidase-labeled goat anti-human IgG was used as conjugate (Jackson Immuno Research Laboratories, Inc., West Grove, PA, Cat #76255) and tetramethylbenzidine (TMB,
RESULTS

Immune response data and blood specimens in Kangaba (Hib-unvaccinated) were collected from May 17 to January 11, 2008, and in Bamako (Hib-vaccinated) from February 26, 2008 to June 11, 2008. A total of 360 children were enrolled, with a single blood specimen being collected from 30 children per age group (6 weeks and 6, 12, 15, 18, and 23 months of age), per site. The volume of serum from each specimen was sufficient so that the PRP titer could be calculated in all 360 specimens. Males and females were almost evenly distributed in both groups: 90 males (50%), 91 females (50%) in rural Kangaba; and 97 males (54%), 93 females (46%) in urban Bamako. Review of the children’s vaccination cards revealed that infants in Bamako and Kangaba received their first dose of pentavalent (with Hib) or quadrivalent (without Hib) vaccine at an average of 6.9 weeks of age (range 6–11.1), the second dose at 12.1 weeks (range 10.1–16.3), and their third dose at 17.3 weeks (range 14.4–22.0), as shown in Table 1. The interval between each sequential vaccination for every child was always greater than 24 days. Thus, the timing of actual Hib vaccination (6.9, 12.1, and 17.3 weeks of age) was later than the ages officially intended by the EPI schedule (6, 10, and 14 weeks of age).

Table 1: Timing of vaccination in Malian children

<table>
<thead>
<tr>
<th>EPI schedule in Mali (study enrollment eligibility)</th>
<th>Administration of DTP/HepB+/Hib</th>
<th>Administration of DTP/HepB+/Hib</th>
<th>Administration of DTP/HepB+/Hib</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPI schedule in Mali (study enrollment eligibility)</td>
<td>6 weeks (6–12 weeks)</td>
<td>10 weeks (10–18 weeks)</td>
<td>14 weeks (14–22 weeks)</td>
</tr>
<tr>
<td>Average timing of vaccination in study subjects (range)</td>
<td>6.9 weeks (6–11.1 weeks)</td>
<td>12.1 weeks (10.1–16.3 weeks)</td>
<td>17.3 weeks (14.4–22.0 weeks)</td>
</tr>
</tbody>
</table>

*EPI = Malian Expanded Program on Immunization.

DISCUSSION

This field study shows that children in urban Bamako, Mali exhibited a robust serologic response to the recently introduced Hib conjugate vaccine given as a component of a pentavalent formulation, in combination with DTwP/HepB, according to the EPI schedule with scheduled immunizations at 6, 10, and 14 weeks of age. Of importance, the immunologic response was sustained throughout the first 2 years of life, which is the highest risk period for invasive Hib disease, without the administration of a reinforcing booster immunization in the second year of life. Including a reinforcing booster dose for toddlers is typical of Hib immunization schedules in most industrialized and transitional countries. An exception was the original Hib conjugate immunization schedule used in the United Kingdom, which did not include a booster dose for toddlers. However, a resurgence of cases occurred in the late 1990s. This was brought under control by a catch-up campaign and eventual introduction of a Hib booster dose at 12 months of age.

With the primary United Kingdom immunization schedule, the PRP antibody GMT for 5-month-olds was 4.6 µg/mL.
(95% CI = 3.51–6.03). In comparison, the GMT for 6-month olds in Mali was higher, reaching 7.73 μg/mL (95% CI = 4.46–13.41). Interestingly, before a reinforcing booster dose, titers in many United Kingdom infants dropped below the long-term protective level (1 μg/mL), as a GMT of 0.88 μg/mL (95% CI = 0.66–1.17) was reported for 12-month olds. By contrast, the GMT for vaccinated Malian 12-month olds in our study remained high at 4.8 μg/mL (95% CI = 2.91–7.92); moreover, the GMT remained close to this level throughout the second year of life (see Figure 1). A similar pattern can be seen in other developing world populations. Among infants in Niger who received DTwP/PRP-T according to the EPI schedule (with immunizations at 6, 10, and 14 weeks of age), a GMT of 6.09 μg/mL was observed at 4.5 months of age and the GMT at 9 months of age was still 2.14 μg/mL.13 Overall, reports of serologic data following immunization with Hib conjugate have been sparse for children in sub-Saharan Africa. Nevertheless, insights can be gleaned from data from other non-industrialized country populations. A 1998 study that directly compared industrialized country (Belgium) infants with developing country (Chile) infants showed significantly higher titers in the latter infants for all components of a quadrivalent combination (DTwP/PRP-T).44

What accounts for the stronger and more enduring anti-PRP responses in infants in developing countries and do the persisting high titers protect against disease? The enhanced anti-PRP responses in developing country infants could derive from immunologic priming consequent to more extensive colonization with Hib or with other bacteria expressing polysaccharides that cross-react with PRP (e.g., E. coli expressing K10).147–50; such immunologic priming may occur even though the infant does not exhibit serum anti-PRP antibodies.

The vaccines co-administered with Hib conjugate can also influence the anti-PRP response. Although industrialized countries have transitioned to acellular pertussis vaccine in the last decade, developing countries still use whole cell pertussis vaccine. The lipopolysaccharide in whole cell pertussis has well-known adjuvant properties mediated by stimulation of TLR4. Consequently, infants immunized with wP/PRP-T compared with aP/PRP-T have stronger responses, better persistence of anti-PRP antibodies, and less risk of vaccine failure.51

These boosting factors may decrease in the future as widespread Hib vaccination and improved socioeconomic conditions (decreased crowding) progressively diminish upper respiratory carriage of Hib.71,52 They would also be lower if in the future acellular pertussis vaccine came to replace whole cell pertussis in the infant combination vaccine. Indeed, rising rates of Hib disease were observed both in the United Kingdom and in The Gambia, 7–9 years after the introduction of Hib vaccination in infancy.53,54 Without a booster dose in the second year of life, however, it is unclear what roles in the rise of Hib disease were played respectively by vaccine failure, fall in Hib immunization coverage, change of Hib vaccine, switch to acellular pertussis vaccine, or diminished natural boosting consequent to decreased carriage.53,54 Therefore, both continued epidemiologic surveillance and serosurvey monitoring are advisable to detect the re-emergence of Hib disease. Moreover, if costs and logistics preclude the administration of a fourth booster dose of Hib in the second year of life, serious consideration must be given to modify the three-dose immunization schedules in developing countries to a regimen of two doses in early infancy followed by the third dose being given at ~9–12 months of age.

Our serologic data suggest that Malian children are protected throughout the critical first 2 years of life. The sero-

---

**Table 2**

<table>
<thead>
<tr>
<th>Age Group</th>
<th>Antibody titers ≥ 1 μg/mL</th>
<th>Antibody titers ≥ 5 μg/mL</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Kangaba</td>
<td>Bamako</td>
</tr>
<tr>
<td>6 mos. (N = 30)</td>
<td>13.3% 90.0% &lt; 0.0001</td>
<td>0.0% 66.7% &lt; 0.0001</td>
</tr>
<tr>
<td>12 mos. (N = 30)</td>
<td>16.7% 93.3% &lt; 0.0001</td>
<td>0.0% 46.7% &lt; 0.0001</td>
</tr>
<tr>
<td>15 mos. (N = 30)</td>
<td>16.7% 76.7% &lt; 0.0001</td>
<td>0.0% 50.0% &lt; 0.0001</td>
</tr>
<tr>
<td>18 mos. (N = 30)</td>
<td>10.0% 83.3% &lt; 0.0001</td>
<td>0.0% 56.7% &lt; 0.0001</td>
</tr>
<tr>
<td>23 mos. (N = 30)</td>
<td>23.3% 93.3% &lt; 0.0001</td>
<td>0.0% 40.0% &lt; 0.0001</td>
</tr>
</tbody>
</table>

*One-sided P value from Fisher’s exact test.
epidemiologic data presented herein corroborate systematic surveillance data from Mali that showed a drastic reduction in the incidence of invasive Hib disease after the introduction of the Hib conjugate vaccine.15 Thirty months after implementation of the Hib conjugate immunization program in Bamako, when the vaccine coverage rate in infants 6–7 months of age was documented to be 81.1% by survey and when 81.5% of infants that age had PRP titers ≥ 1 μg/mL, Hib incidence had decreased by 86%.15 This effect carried over into the 12–23 months age group after the vaccinated infants reached toddler age.15 These data support the hypothesis that the high PRP antibody titers found in the vaccinated Malian pediatric population protect against Hib disease. Thus, the sustained immune response persists through the second year of life, despite lack of a booster dose in the second year of life, and epidemiologic data show that protection also persists for the 12–23 months age group. Moreover, indirect protection may also be provided to unvaccinated infants and non-target age groups caused by decreased transmission of Hib organisms, because ~50% of vaccinated children in Bamako had serum anti-PRP antibody above a level that is thought to inhibit upper respiratory tract carriage (≥ 5 μg/mL).15 Our study highlights the widespread serological evidence immunity in Malian infants following programmatic introduction of Hib conjugate vaccine and evidence that seroprotection endures through at least the second year of life. The results also show the susceptibility of infants and toddlers in areas where the Hib vaccine program had not yet reached. These population-based seroprotection data complement and corroborate the earlier demonstration of the drop in invasive Hib disease burden in Malian infants and toddlers where Hib vaccine had been introduced and provide further justification for including Hib conjugate in the routine EPI schedule for all Malian infants.

Received December 28, 2011. Accepted for publication March 3, 2012.

Acknowledgments: We thank Mardi Reymann, Lilian Cuberos, and Inna Rusananova from the CVD Applied Immunology Section for technical assistance measuring Hib antibodies. We also thank William Blackwelder, the senior biostatistician of the CVD, for his valuable input in the statistics section.

Financial Support: Grant from the Bill and Melinda Gates Foundation to Myron M. Levine.

Authors’ addresses: Julia Hutter, Marcela F. Pasetti, Milagritos D. Tapia, and Myron M. Levine. University of Maryland School of Medicine, Center for Vaccine Development, Baltimore, MD. E-mails: jhutter@gmail.com, mpasetti@medicine.umd.edu, and mllevine@medicine.umd.edu. Doh Sanogo and Samba O. Sow, Ministry of Health, Centre pour le Développement des Vaccins – Mali, Ex-Institut Marchoux, Bamako, Mali, E-mails: sanogodoh@yahoo.fr and ssow@medicine.umd.edu.

REFERENCES


